Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
681 – 700
of
3979
Dosing Recommendations for Prevention and Treatment of Malaria
https://clinicalinfo.hiv.gov/table/dosing-recommendations-prevention-and-treatment-malaria
Table 1. Primary Prophylaxis of Opportunistic Infections in Children with and Exposed to HIV— Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table/table-1-primary-prophylaxis-full
Table 2. Secondary Prophylaxis of Opportunistic Infections in Children with and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-2-secondary-prophylaxis-full
Table 3. Treatment of Opportunistic Infections in Children with and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-3-treatment-full
Table 4. Common Drugs Used for Treatment of Opportunistic Infections in HIV-Infected Children: Preparations and Major Toxicities
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table/table-4-common-drugs-used-treatment-opportunistic-infections-hiv-infected-children
Table 5. HIV-Related Laboratory Monitoring Schedule for Pregnant People With HIV
https://clinicalinfo.hiv.gov/guidelines/perinatal/antepartum-care-initial-evaluation-monitoring-hiv-assessments-during-pregnancy-full
Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-drug-use-pregnant-full
Supplemental Table 1. Results of Major Studies on Antiretroviral Interventions to Prevent Perinatal HIV Transmission
https://clinicalinfo.hiv.gov/guidelines/perinatal/review-clinical-trials-arv-interventions-prevent-hiv-transmission-full
Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis
https://clinicalinfo.hiv.gov/table/appendix-c-clinical-trial-efficacy-data-daily-oral-tenofovir-disoproxil-fumarateemtricitabine
Raltegravir
https://clinicalinfo.hiv.gov/table/raltegravir
Table A. Summary of IMPAACT P1066 Cohorts and Participation
https://clinicalinfo.hiv.gov/table/table-summary-impaact-p1066-cohorts-and-participation
Table B. Raltegravir Pharmacokinetic Parameters for Raltegravir-Naive and Raltegravir-Exposed Neonates
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/raltegravir-full
Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy<sup>a</sup>
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/clinical-and-laboratory-monitoring-pediatric-hiv-infection-full
Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/cns-toxicity-full
Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dyslipidemia-full
Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/gastrointestinal-effects-full
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/hematologic-effects-full
Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/hepatic-events-full
Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/insulin-resistance-asymptomatic-hyperglycemia-diabetes-mellitus-full
Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lactic-acidosis-full
Pagination
First page
«
Previous page
‹
…
Page
31
Page
32
Page
33
Page
34
Current page
35
Page
36
Page
37
Page
38
Page
39
…
Next page
›
Last page
»